MetLife Investment Management LLC Purchases 12,949 Shares of Bioventus Inc. (NYSE:BVS)

MetLife Investment Management LLC raised its position in shares of Bioventus Inc. (NYSE:BVS) by 129.1% in the third quarter, HoldingsChannel reports. The firm owned 22,981 shares of the company’s stock after buying an additional 12,949 shares during the quarter. MetLife Investment Management LLC’s holdings in Bioventus were worth $275,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also made changes to their positions in the company. Dimensional Fund Advisors LP grew its stake in shares of Bioventus by 100.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 117,496 shares of the company’s stock valued at $676,000 after purchasing an additional 58,954 shares during the period. Rhumbline Advisers grew its stake in shares of Bioventus by 5,367.9% during the 2nd quarter. Rhumbline Advisers now owns 52,437 shares of the company’s stock valued at $302,000 after purchasing an additional 51,478 shares during the period. Segall Bryant & Hamill LLC bought a new stake in shares of Bioventus during the 3rd quarter valued at about $4,515,000. Bank of New York Mellon Corp bought a new position in shares of Bioventus during the 2nd quarter valued at approximately $647,000. Finally, Royce & Associates LP bought a new position in shares of Bioventus during the 3rd quarter valued at approximately $8,337,000. 62.94% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on BVS shares. Canaccord Genuity Group boosted their price objective on Bioventus from $12.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. Craig Hallum boosted their price objective on Bioventus from $12.00 to $17.00 and gave the company a “buy” rating in a research note on Friday, September 27th.

Bioventus Stock Up 0.3 %

NYSE BVS opened at $11.68 on Monday. The stock’s 50 day moving average is $12.14 and its 200 day moving average is $9.37. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. Bioventus Inc. has a 12 month low of $3.90 and a 12 month high of $14.38. The stock has a market cap of $947.83 million, a PE ratio of -19.15 and a beta of 0.79.

Bioventus (NYSE:BVS) last posted its quarterly earnings results on Tuesday, November 5th. The company reported $0.06 EPS for the quarter, hitting analysts’ consensus estimates of $0.06. Bioventus had a positive return on equity of 15.61% and a negative net margin of 7.11%. The company had revenue of $138.96 million for the quarter, compared to analysts’ expectations of $132.57 million. During the same period in the previous year, the firm earned $0.05 EPS. Research analysts predict that Bioventus Inc. will post 0.41 EPS for the current fiscal year.

Bioventus Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.